

Endorsed by:
ANZSCTS



TOGA

Thoracic Oncology Group Australasia

A central graphic featuring a glowing lightbulb held by a hand, with a network of blue and red nodes and lines extending from it, set against a dark blue background with light rays.

Charting New Horizons: A Multidisciplinary Approach to Lung Cancer Screening and Care

Annual Scientific Meeting

Pre-event Workshops: 31 July 2024 | ASM: 1-2 August 2024

Sheraton Grand Sydney Hyde Park

WELCOME

WELCOME TO TOGA'S ASM 2024

The TOGA 2024 Annual Scientific Meeting (ASM) focuses on the topical areas of thoracic cancer treatment and research from the perspective of TOGA's mission to prevent, treat, and cure thoracic cancers through research, clinical trials, education, and advocacy.

This year's underlying theme is *'Charting New Horizons: A Multidisciplinary Approach to Lung Cancer Screening and Care'*.

TOGA, in collaboration with our event partners, is excited to host this year's annual event, endorsed by the Australian & New Zealand Society of Cardiac & Thoracic Surgeons (ANZSCTS).

THE TOGA 2024 ASM PROVIDES:

- **Connection and collaboration** with some of the most innovative and influential minds in healthcare and clinical research from across the lung cancer community. This includes respiratory medicine, medical oncology, radiation oncology, surgery, pathology, nursing, allied health, and consumers involved in research.
- **Learning of advances** in quality thoracic cancer care, and to discuss their application in the local healthcare environment and to develop cross-cutting research capacity with the multidisciplinary membership.

The 2024 program features a variety of international and local speakers presenting topical issues in thoracic cancer research, including lung cancer screening, immunotherapy treatment, the future influence of biomarker-driven treatments for lung cancer, and more.

Additionally, oral and poster abstract sessions will provide an opportunity for members to present their local thoracic cancer research projects.

We acknowledge the generous support of our sponsors for the 2024 ASM and welcome their representatives to the ASM.

INTERNATIONAL SPEAKERS

We are pleased to be joined by:

- **Professor Philip Crosbie**, Senior Lecturer and Honorary Consultant in Respiratory Medicine at the University of Manchester, who will share his expertise and valuable insights into the UK's experience with lung cancer screening.
- **Professor Myung-Ju Ahn** from the Department of Medicine, Sungkyunkwan University School of Medicine in Seoul, who will discuss *'Treatment Strategies to Overcome Osimertinib Resistance'* and provide recent updates in small cell lung cancer.
- **Dr Jessica Donington**, Professor of Surgery and Chief of the Section of Thoracic Surgery at the University of Chicago, who will talk about *'Resectable Lung Cancer & Immunotherapy'* and *'Novel Indications for Surgery in Advanced Stage Lung Cancer'*.



KEY SESSIONS

- **Lung Cancer Screening Multidisciplinary Workshop | Wednesday 31 July, 1:00pm**
This workshop aims to provide an overview of the progress in the National Lung Cancer Screening Program (LCSP) implementation and the changes lung cancer screening will bring to each of the major clinical disciplines involved in quality lung cancer care.
- **ASM Dinner | Thursday 1 August, 6:30pm**
A night of fun, fine food, and music with the opportunity to meet and network with your fellow colleagues.
- **Microsatellite Breakfast Symposium | Friday 2 August, 7:00 am**
Sponsored by Roche, the *'Question the experts - Emerging clinical questions when personalising treatment in Stage I-III NSCLC'* is an overview of change that is expected to influence treatment in Stage I-III NSCLC.
- **Debate | Friday 2 August, 3:35pm**
A light-hearted debate to close out the ASM.
- **Working group meetings | Various times, see program for details**
Various meetings are scheduled throughout the two days.
Open to TOGA Working Group Committee Members Only.

The Local Organising Committee worked diligently to deliver an excellent program, and we hope you enjoy the event.

ASM CONVENOR WELCOME MESSAGE



**Dr Tracy Leong MBBS (Hons) FRACP
MPH PhD CCPU SpecCertClinLead
Director of Bronchoscopy
Respiratory and Sleep Physician
Austin Health
ASM 2024 Convenor**

"It is my absolute honour and delight to convene the TOGA ASM for 2024 which will promote 'Charting New Horizons: A Multidisciplinary Approach to Lung Cancer Screening and Care'.

At this exciting time of advances in the field of lung cancer, the TOGA ASM represents a key meeting to learn from international and national experts, develop collaborations with colleagues, and connect with valued members of the lung cancer community.

Together with a stellar multi-disciplinary organising team, I greatly look forward to welcoming you in August to inspire and be inspired."

WEDNESDAY JULY 31



TOGA LUNG CANCER SCREENING MULTIDISCIPLINARY WORKSHOP

MEETING ROOM: Hyde Park Room
CONVENOR: Dr Tracy Leong
(Face-to-Face Only)

TIME	TOPIC	PRESENTED BY
12:00pm	Registrations Hyde Park Foyer, Level 2	
1:00pm	Welcome and Introductions	Dr Tracy Leong
1:05pm	Update on National Lung Cancer Screening Program (NLCSPP)	Prof Vivienne Milch Ms. Lisa Schofield PSM
1:15pm	Impact of NLCSPP for Aboriginal and Torres Strait Islander Peoples	A/Prof Lisa Whop
1:25pm	Impact and Updates related to Respiratory Medicine	Dr Annette McWilliams
1:40pm	Impact and Updates related to Radiology	Dr Diane Pascoe
1:55pm	Nurse-Led Pulmonary Nodule Clinic	Ms Siobhan Dormer
2:10pm	Panel Discussion	All Speakers
2:40pm	Afternoon Tea Hyde Park Foyer, Level 2	
3:10pm	Impact and Updates related to Surgery	A/Prof Gavin Wright
3:25pm	The Impact of Lung Cancer Screening on Radiation Oncology	Prof Shalini Vinod
3:40pm	Impact and Updates related to Medical Oncology	Dr Malinda Itchins
3:50pm	Impact and Updates related to Psycho-Oncology	A/Prof Haryana Dhillon
4:00pm	NLCSPP Program Guidelines	A/Prof Nicole Rankin
4:15pm	Panel Discussion	All Speakers + Anthony Barrett, Consumer Advocate
4:40pm	Closing	Dr Tracy Leong
4.45pm	Finish	

SPONSORED BY:



THURSDAY AUGUST 1

TIME	TOPIC	PRESENTED BY
7:30am	Sheraton Grand Sydney Hyde Park, Phillip II Room, Level 2	
7:30-8:15am	SCLC/Mesothelioma Working Group Committee Meeting (Open to TOGA Working Group Committee Members Only) (face-to-face only)	Chairs: A/Prof Surein Arulananda Dr Rebecca Tay
8:15-8:30am	Embedding Translational Research in TOGA Clinical Trials (Open to TOGA Working Group Committee Members Only) (face-to-face only)	Chairs: Prof Kate Sutherland A/Prof Venessa Chin
8:30-9:15am	Supportive Care Working Group Committee Meeting (Open to TOGA Working Group Committee Members Only) (face-to-face only)	Chairs: A/Prof Michael Franco A/Prof Haryana Dhillon



Professional Photography

A professional photographer will be on-site during the following times to take photos, so make sure to get your professional photo taken.

- Thursday, 1 August from 9:30am to 1:30pm
- Friday, 2 August from 12:30pm to 4:30pm

TIME	TOPIC	PRESENTED BY
9:00am	Registrations Grand Ballroom Foyer, Level 2	
9:45am	Welcome to Country	
10:00am	Welcome	Dr Tracy Leong
10:10am	Opening Address	Chair: Dr Tracy Leong Mr Anthony Barrett, Consumer Advocate
10:30am	Plenary: Lung Cancer Screening Implementation: A UK Perspective	Chair: Dr Tracy Leong Prof Philip Crosbie
	Additional Considerations for Eligibility in Future Screening Programs Beyond Smoking History	Chair: Dr Tracy Leong
11:05am	Limitations of the PLCO Model	Dr Annette McWilliams
11:15am	Occupational Lung Disease	Prof Fraser Brims
11:25am	Other Lung Cancer Risk Factors – The Message from TALENT	Prof Emily Stone
11:35am	Panel Discussion	Dr Annette McWilliams Prof Fraser Brims Prof Emily Stone
11:45am	Plenary: Resectable Lung Cancer & Immunotherapy	Chair: Dr Maggie Moore Dr Jessica Donington

THURSDAY AUGUST 1

Visit the poster boards located in the Grand Ballroom Foyer on level 2 during Thursday & Friday lunch break.


TIME	TOPIC	PRESENTED BY
12:20pm	Protons and Particle Therapy	Chair: Dr Fiona Hegi-Johnson Dr Michelle Li
12:40pm	Lunch Grand Ballroom Foyer & Ballroom II, Level 2	
1:40pm	Equitable Access to Quality Care and Clinical Trials	Chair: A/Prof Haryana Dhillon
1:45pm	Geriatric Oncology: Striving for the Optimal Management of Thoracic Malignancies in Older Individuals	Dr Michael Krasovitsky
2:00pm	Insights into the Barriers and Enablers Influencing Clinical Trial Participation in the Arabic-Speaking Community	Dr Rayan Saleh Moussa
2:15pm	Lung Cancer Screening for Aboriginal and Torres Strait Islander Peoples: An Opportunity to Address Health Inequities	A/Prof Lisa Whop
2:30pm	Navigating Healthcare in Regional Settings: Challenges and Solutions for Accessing Quality Care	A/Prof Bryan Chan
2:45pm	Panel Discussion	Dr Michael Krasovitsky Dr Rayan Saleh Moussa A/Prof Lisa Whop A/Prof Bryan Chan
3:00pm	Afternoon Tea Grand Ballroom Foyer & Ballroom II, Level 2	
3:30pm	ORAL ABSTRACTS	Chairs: A/Prof Nicole Rankin Dr Shalini Subramaniam
3:30pm	First Sixty Patients in Australia First Lung Cancer Biobank (TRACKER)	Dr Sarah Yeo
3:45pm	Impacts of performance status on survival in Small Cell Lung Cancer: Real world evidence from a retrospective registry based cohort study	Dr Wasek Faisal
4:00pm	Comparison of 2D and 3D cell culture model as a platform for chemo drug screening in mesothelioma: in vitro and in vivo	Dr. Huaikai (Peter) Shi
4:15pm	Lung Cancer Screening using MSAC criteria: a missed opportunity for most	Ms Jacqueline Logan
4:30pm	The Long-term Psychosocial Impact in New South Wales Participants of the International Lung Screening Trial (ILST)	Dr Trent Chang-Wei Wu
4:45pm	Effect of Rapid Access Lung Cancer Clinic (RALCC) on Timeliness of Diagnosis and Management of Lung Cancer	Dr Cheng Leong Yeo
5:00pm	Immunotherapy decision-making in driver-negative, metastatic NSCLC with high PD-L1 expression: Real World Analysis	Dr Samuel Smith
5:15pm	Identification of Intrinsic and Extrinsic Factors Contributing to Osimertinib Resistance	Dr Mark Adams
5:30pm	Finish	





THURSDAY AUGUST 1

TIME	TOPIC	PRESENTED BY
5:30pm	Sheraton Grand Sydney Hyde Park, Phillip II Room, Level 2	
5:30-6:30pm	Advanced NSCLC Working Group Committee Meeting (Open to TOGA Working Group Committee Members Only) (face-to-face only)	Chairs: Dr Malinda Itchins Prof Kenneth O'Byrne
6:30pm	Dinner Sheraton Grand Sydney Hyde Park, Hyde Park Room, Level 2	
6:30pm	Guest Arrival/Pre Dinner-Drinks Performance by Pianist	
7:20pm	Guest Seating	
7:30pm	Entrée	
8:15pm	Main	
9:00pm	Dessert Followed by Tea & Coffee	



New Horizons in Small Cell Lung Cancer

A meeting proudly sponsored by Amgen, focusing on current treatments and future therapies for Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Date: 12 August 2024

Venue: Online - Webinar
Registrations Open

thoraciconcology.org.au/education/new-horizons-in-es-sclc/

TOGA
Thoracic Oncology Group Australasia

FRIDAY AUGUST 2

MICROSATELLITE BREAKFAST SYMPOSIUM

Question the Experts - Emerging Clinical Questions when Personalising Treatment in Stage I-III NSCLC




TIME	TOPIC	PRESENTED BY
6:30am	Breakfast Grand Ballroom Foyer & Ballroom II, Level 2	
7:00am	Sheraton Grand Sydney Hyde Park, Grand Ballroom I, Level 2	Chair: A/Prof Melissa Moore
7:00am	Welcome and Introduction	A/Prof Melissa Moore
7:05am	Immunotherapy in Early-Stage NSCLC	A/Prof Zarnie Lwin OAM
7:10am	Lung Cancer Screening and Neoadjuvant Immunotherapy - How Will These Change Future Thoracic Surgery?	Prof Christopher Cao
7:15am	The Changing Role of Radiation Therapy in Early-Stage NSCLC	A/Prof Harriet Gee
7:20am	Genomic Testing and Targeted Therapies in Early-Stage NSCLC	A/Prof Bryan Chan
7:25am	Panel Discussion	All Presenters
7:55am	Closing	A/Prof Melissa Moore
8:00am	Finish	
8:00am	Registrations Grand Ballroom Foyer, Level 2	
8:30am	Welcome	Dr Tracy Leong
8:35am	Plenary: Treatment Strategies to Overcome Osimertinib Resistance	Chair: Dr Maggie Moore Prof Myung-Ju Ahn
9:10am	Translational Research from DREAM Clinical Trial	Chair: Prof Nick Pavlakis Dr Melvin Chin
9:30am	Improving Genomic Testing Rates for Inoperable Lung Cancer Patients	Chair: Dr Maggie Moore A/Prof David Fielding
9:50am	Clinical Quality Indicators in Lung Cancer Care	Chair: Ms Amy O'Donnell Prof Fraser Brims
10:10am	Future of Lung Cancer Nursing in Australia	Chair: Dr Vanessa Brunelli Ms Anne Mellon
10:45am	Morning Tea Grand Ballroom Foyer & Ballroom II, Level 2	
11:15am	Clinical Trials Session	A/Prof Thomas John
	ILLUMINATE Results: A Phase 2 trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR Tyrosine Kinase Inhibitors (TKIs)	Prof Chee Lee
	SHERLOCK: Sotorasib with bEvacizumab firSt Line cOmbined with Chemotherapy for KRAS G12C NSCLC	Prof Chee Lee
	OCEANIC: Osimertinib plus Chemotherapy Evaluation in Adjuvant NSCLC incorporating CtdNA	A/Prof Thomas John
	ADOPT-Lung: A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab, and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer	Dr Malinda Itchins
	DYNAMALK: DYNAMic ctDNA profiling in ALK+ NSCLC: a study of the AUstralian Registry and biObank of thoRacic cAncers (AURORA)	Dr Malinda Itchins
	ALKTERNATE: A single arm multi-centre translational proof of concept study investigating the safety and efficacy of alternating lorlatinib with crizotinib in a pre-treated advanced ALK-rearranged non small cell lung cancer (NSCLC) population with disease progression on a 2nd generation ALK Tyrosine Kinase Inhibitor (TKI)	Dr Malinda Itchins
	AURORA: AUstralian Registry and biObank of thoRAcic cancers	Dr Malinda Itchins
	CHEST-RT: Chemotherapy and Immunotherapy in Extensive Stage Small cell with Thoracic Radiotherapy	Dr Sagun Parakh
	PRIME-Lung: Primary Radiotherapy In MEtastatic Lung Cancer	A/Prof Thomas John

FRIDAY AUGUST 2

TIME	TOPIC	PRESENTED BY
	MODERN-LUNG: Safety of Moderately Hypofractionated Chemoradiation for Locally Advanced, Unresectable Non-Small Cell Lung Cancer: Preliminary Results of a Single Arm, Prospective Study	Dr Jane Ludbrook
12:40pm	Closing	A/Prof Thomas John
12:45pm	Lunch Grand Ballroom Foyer & Ballroom II, Level 2	
1:45pm	Membership Meeting	Chair: Prof Nick Pavlakis
2:15pm	Lung Adenocarcinoma Promotion by Air Pollutants	Chair: Dr Tracy Leong Prof Philip Crosbie
2:35pm	Recent Updates in Small Cell Lung Cancer	Chair: Prof Nick Pavlakis Prof Myung-Ju Ahn
2:55pm	Novel Indications for Surgery in Advanced Stage Lung Cancer	Chair: Prof Christopher Cao Dr Jessica Donington
3:15pm	Local Management with Radiotherapy for Oligopersistent and Oligoprogressive Disease after Immunotherapy and TKI's	Chair: Dr Fiona Hegi-Johnson Dr Dasantha Jayamanne

THE GREAT DEBATE

3:35pm	Sheraton Grand Sydney Hyde Park Grand Ballroom I, Level 2	Chair: Prof Michael Boyer
3:35pm	Cancer Care navigators will outdo the need for specialist lung cancer nurses	
3:40pm	Affirmative	A/Prof Bryan Chan
3:45pm	Negative	Dr Vanessa Brunelli
3:50pm	Rebuttal	A/Prof Bryan Chan / Dr Vanessa Brunelli
3:55pm	Three birds, one stone: PET is the future of cancer screening	
3:57pm	Affirmative	Dr Geoffrey Schembri
4:02pm	Negative	Dr Deme Karikios
4:07pm	Rebuttal	Dr Geoffrey Schembri / Dr Deme Karikios
4:12pm	N2 disease in the IO era: radiation versus the knife	
4:14pm	Affirmative	Dr Jane Ludbrook
4:19pm	Negative	Mr Stephen Barnett
4:24pm	Rebuttal	Dr Jane Ludbrook / Mr Stephen Barnett
4:29pm	Awards and Closing	
4:35pm	Abstract/Poster Awards and Conference Close	Dr Tracy Leong
4:45pm	Finish	



SPONSORS

Thank you for
your contribution.
We gratefully
acknowledge your
sponsorship.

PLATINUM



At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we've been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world's most challenging diseases. For more information, visit www.msd.com.

GOLD



Boehringer Ingelheim is a research-driven biopharmaceutical company targeting areas of high unmet medical need to improve and extend the lives of humans and animals. Family-owned since 1885, we are among the top 20 companies in the industry. We have developed a combination of smart approaches including cancer cell-directed and immuno-oncology investigational therapies to develop a robust pipeline, for the benefit of people living with cancer. Our ambition is to deliver meaningful advances with the ultimate goal to cure a range of cancers including dedifferentiated liposarcoma and non-small-cell lung cancer.



One way or another, cancer touches all our lives. Which is why nothing is more personal, or more urgent, than our goal to find cures for cancer and to deliver on our purpose: breakthroughs that change patients' lives.

SILVER



Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory disorders and many others. In oncology, Amgen is dedicated to delivering new therapies to patients with complex cancers, where there remains significant unmet need.

SILVER



AstraZeneca in Oncology

AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients. The Company's focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience. AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

For more information, please visit www.astrazeneca.com.au.



Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients' lives through science.



At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.

Learn more at www.jnj.com/.



Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare.

Roche is one of the world's largest biotech companies, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also a world leader of in vitro diagnostics and tissue-based cancer diagnostics. In recent years, Roche has invested in genomic profiling and real-world data partnerships.

For more information, visit www.roche-australia.com.

SPONSORS

SILVER



Turner Freeman Lawyers are a national plaintiff law firm with a proud history of over 70 years. We have a breadth of expertise across all personal legal matters yet retain a deep specialisation in personal injury law. Our Legal Services include Personal Injury Law, Asbestos Disease and Silica Compensation, Hearing Loss, Institutional Abuse, Superannuation, Total Permanent Disability, Wills and Estates and Insurance. We are Australia's largest and most experienced asbestos litigation firm and our years of experience in each field have helped us build long-standing relationships with some of the best medical and rehabilitative support professionals around. Our philosophy of long-term commitment also encompasses our clients, many of whom appreciate the personalised service and attention to special needs. If you have any questions about your current situation or require further information, please call us on 13 43 63 or fill in our online [enquiry form](#).

BRONZE



Ariceum Therapeutics is a private company focused on developing novel targeted radiopharmaceuticals for the treatment of cancer.



Bayer: Science for a better life

Bayer is a global life science company with expertise in healthcare and agriculture. The company has had a presence in Australia since 1925 and has a long-term commitment to the health and nutrition of all Australians and New Zealanders. As people live longer and the population continues to grow both locally and beyond, Bayer is one of the few companies that takes a comprehensive view of these issues. Guided by our purpose – Science for a better life – we apply our global scientific expertise in healthcare and agriculture to deliver innovations locally to help people and the planet thrive.

Bayer employs almost 900 people across Australia and New Zealand and is dedicated to servicing the needs of rural and remote communities. Bayer embraces and encourages its employees' unique identities and advances a culture of inclusion and diversity across gender, LGBTQIA+, generations, disability and race.

For further information visit www.bayer.com.au.



BeiGene is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 10,000 colleagues spans five continents. To learn more about BeiGene, please visit www.beigene.com.au and follow us on LinkedIn, X (formerly known as Twitter), and Facebook.

Get to know
your industry
representatives.
Visit the sponsor
stands located in
the Exhibition
area.

BRONZE



Daiichi Sankyo is a global pharmaceutical company on a mission to become a global top ten leader in oncology by 2030. This was driven by the discovery of our proprietary DXd antibody drug conjugate (ADC) technology, which is poised to redefine the treatment of cancer. In Australia, we are growing a team with a passion for innovation and compassion for patients. We are working with more than 40 sites on 10 trials evaluating our DXd ADCs, with additional studies planned. We are committed to developing new ideas and innovations in partnership with local researchers, clinicians, patients, patient advocates and government to enrich the lives of those impacted by cancer.



GenesisCare is the largest private provider of integrated cancer care in Australia. We aim to change the face of cancer care with modern treatments and techniques designed to enable the best possible life outcomes for patients. We provide care to approximately 30,000 patients a year across 49 locations in metro and regional Victoria, New South Wales, Queensland, South Australia, and Western Australia. We strive to offer our patients personalised, high-quality care throughout their cancer journey.

For more information, visit www.genescare.com.



Hummingbird Bioscience is a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases. The Hummingbird Bioscience model combines computational and systems biology with wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. The company harnesses this integrated approach across target identification and patient selection, enabling the team to increase the efficiency of translating novel scientific insights while reducing the inherent risk in drug discovery and development. The company is currently developing two clinical-stage assets: HMBD-001, a humanized anti-HER3 monoclonal antibody targeting a novel epitope on HER3, and HMBD-002, a humanized anti-VISTA IgG4 monoclonal antibody. Both programs are currently in Phase I studies. At Hummingbird Bioscience, the commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic.



At Illumina our mission is to improve human health by unlocking the power of the genome. Our sequencing by synthesis chemistry is used to generate high-accuracy DNA and RNA sequence data in studies around the globe. Our microarrays also provide accurate, high-throughput genotyping for a range of applications. Through innovation and collaboration, we have developed comprehensive genomic profiling tools that help investigators identify biomarkers, describe tumor biology, and inform therapy selections. The opportunity to transform tumor profiling with innovative assays, new companion diagnostics, and liquid biopsy tools inspires us to push the boundaries of what is possible and drive innovation.



Lilly unites caring with discovery to create medicines that make life better for people around the world. Three long-established core values guide Lilly in all that we do:

- **Integrity:** We conduct our business consistently with all applicable laws. We are honest in our interactions with patients, customers and employees.
- **Excellence:** We pursue pharmaceutical innovation, provide high-quality products and strive to deliver superior business results.
- **Respect for People:** We maintain an environment built on mutual respect, openness and individual integrity. We're committed to the wellbeing of all people who interact with our company: patients, customers, employees, shareholders and communities.

SPONSORS

BRONZE



Maurice Blackburn Lawyers are Australia's #1 plaintiff law firm.

We believe everybody deserves access to justice, not just those who can afford it. That's why for over 100 years, our firm has been helping and guiding our clients with their legal needs.

For more than 30 years, our experienced lawyers have successfully represented hundreds of clients and their families in complex and sensitive asbestos and silica-related cases, helping them to understand their eligibility and the processes involved when making a compensation claim.

As a national firm practicing in many areas of the law, we have a full suite of legal services and experience. Aside from asbestos and personal injury lawyers, we can also assist clients with any superannuation and insurance claims, the drafting of an up-to-date Will, and our employment lawyers can advise those exposed to asbestos on their work rights.

We employ over 1,000 of the country's brightest, most compassionate and determined minds. With local knowledge and a national network of experts, we have the experience you can count on.



Medison is a global pharma company focused on providing access to highly innovative therapies to patients in international markets, with presence in Central and Eastern Europe, Canada, Latin America, Asia Pacific, Australia and Israel. Medison is the first to create a global commercialization platform for highly innovative therapies, helping to save and improve lives by making the best available novel treatments accessible to patients in international markets. Medison has a track record of global partnerships with leading pharmaceutical and biotech companies seeking to expand their global reach.

To learn more visit www.medisonpharma.com.



We are Merck, a vibrant science and technology company, based in Australia for over 50 years.

Science is at the heart of everything we do. It drives the discoveries we make and the technologies we create. The passion of our curious minds makes a positive difference to millions of people's lives every day.

Our Healthcare team is here for people at every step, helping create, improve and prolong life. Our goal is to discover personalised ways to treat the most challenging diseases, such as multiple sclerosis and cancer and to help people to achieve their dream of becoming parents.

Everything we do is fuelled by a belief in science and technology as a force for good. A belief that has driven our work since 1668 and will continue to inspire us to find more joyful and sustainable ways to live.

Visit us: www.merck.com.au. Follow on: [LinkedIn](#) and [X](#).



Omico is changing the way we fight cancer by accelerating access to precision oncology. We are a national, independent, not-for-profit organisation, uniting Australia's world-class cancer institutes, researchers, clinicians, industry partners and government like never before. By leveraging a nationwide network of expertise and resources, we aim to improve outcomes for all Australian cancer patients. With fast-tracked molecular and genomic screening, biomarker-led trial set up and patient enrolment from the entire nation, we're accelerating access to next generation treatments and preventive strategies.

Get to know your industry representatives. Visit the sponsor stands located in the Exhibition area.

BRONZE



Slater & Gordon are a leading Australian consumer law firm who access justice for all people, treating every client with care and commitment to make their tomorrow better than today. We lead the way in Asbestos, Silicosis and dust disease claims and have acted for more than 2500 people suffering from asbestos related diseases over the past 35 years throughout Australia. We help those suffering from dust diseases and their families by taking care of their legal needs so they can focus on their treatment, health, and the journey ahead. With over 85 years' experience Slater & Gordon have specialist legal teams working across a broad range of areas. We innovated No Win, No Fee* so that all Australians can have access to quality legal representation and since 2009 we have provided free social work support to our personal injury clients and their families, recognising that obtaining correct legal entitlements is only one of the many issues people face after a life-changing incident. We look forward to continuing our work helping those suffering from dust diseases today and in the future.



Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Ion Torrent, Fisher Scientific, Unity Lab Services, Patheon and PPD.



Lung Cancer Preceptorship

The TOGA lung cancer preceptorship is the principal TOGA educational event. The two-day workshop is an intensive and active learning program for medical trainees, fellows and nurses interested in developing their clinical knowledge and expertise in lung cancer management.

Date: 22-23 November 2024
Venue: Amora Brisbane
Registrations Open in August





TOGA

PO Box 1103 Thornbury VIC 3071

Ph: +61 3 9087 3550 | **Email:** info@thoraciconcology.org.au | **ABN:** 47 641 984 198